{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,3]],"date-time":"2026-07-03T01:30:04Z","timestamp":1783042204853,"version":"3.54.6"},"reference-count":38,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,7,24]],"date-time":"2021-07-24T00:00:00Z","timestamp":1627084800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,7,24]],"date-time":"2021-07-24T00:00:00Z","timestamp":1627084800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100000069","name":"National Institute of Arthritis and Musculoskeletal and Skin Diseases","doi-asserted-by":"publisher","award":["R01AR073324"],"award-info":[{"award-number":["R01AR073324"]}],"id":[{"id":"10.13039\/100000069","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["P30DK063491"],"award-info":[{"award-number":["P30DK063491"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["T32AR064194"],"award-info":[{"award-number":["T32AR064194"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["1R01AR0690000-01"],"award-info":[{"award-number":["1R01AR0690000-01"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Arthritis Res Ther"],"published-print":{"date-parts":[[2021,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Oxylipins are biological lipids that have been implicated in inflammation. We previously found that certain oxylipins correlated with clinical manifestations in psoriatic arthritis (PsA) patients. Here, we compare oxylipin profiles in PsA patients and those with psoriasis (PsO) without inflammatory arthritis to identify oxylipins that associate with specific disease manifestations to better understand disease pathogenesis and identify new biomarkers.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>Consecutive patients with PsA (who met the CASPAR classification criteria for PsA) and PsO were recruited from the Rheumatology Outpatient Clinic. A thorough clinical examination was performed, including entheseal (Leeds enthesitis index (LEI)) and joint involvement (SJC\/TJC 66\/68). Patients were evaluated for pain and global disease activity on a visual analog scale (VAS) ranging from 0 to 100. This was followed by disease activity scores calculation: cDAPSA (Disease Activity Index for Psoriatic Arthritis) and Psoriasis Area and Severity Index (PASI). Serum oxylipins were determined by mass spectrometry and their association with clinical characteristics (PASI\/LEI and cDAPSA) was analyzed using Metaboanalyst 4.0 and R version 3.6.1.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>Twenty PsO (average age 52 [10.8], 55% males) and 19 PsA patients (average age 60.5 [11.4], 63.1% males) were included. PsO patients had an average body mass index (BMI) of 33.7 (6.84) and an average PASI of 3.8 (4.2). PsA patients had an average BMI of 31.9 (5.6), TJC of 9.3 (10.41), SJC of 3.7 (4.23), with an average cDAPSA of 23.3 (11.4). 63.1% of PsA patients had enthesitis (average LEI 2.2 [3]) and the same percentage had psoriasis (average PASI 3(5]). Sera were analyzed for oxylipin levels. PsO and PsA patients with higher PASI score (&gt;\u20092.5) had significantly lower serum concentrations of pro-inflammatory oxylipins, most of them arachidonic acid derived (AA). Oxylipin profiling did not associate with cDAPSA. Interestingly, several AA-derived oxylipins (5,15 di-HETE (5S,15S-dihydroxy-6E,8Z,10Z,13E-eicosatetraenoic acid), 5-oxoETE (5-Oxo-eicosatetraenoic acid), PGE2 (prostaglandin E2), 11bPGE2 (11 beta prostaglandin D2), and LTB4 (leukotriene B4)) were significantly increased in PsA patients with enthesitis compared to those without.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>The AA-derived proinflammatory oxylipins were lower in both PsO and PsA patients with higher skin scores. Joint disease activity was not associated with the concentrations of oxylipins. Yet, enthesitis was associated with an increase of AA-derived pro-inflammatory oxylipins in PsA patients. Further studies are needed to determine whether oxylipin profiling can be a good biomarker of enthesitis in PsA patients.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s13075-021-02575-y","type":"journal-article","created":{"date-parts":[[2021,7,24]],"date-time":"2021-07-24T19:04:01Z","timestamp":1627153441000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":23,"title":["Differences in oxylipin profile in psoriasis versus psoriatic arthritis"],"prefix":"10.1186","volume":"23","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9547-218X","authenticated-orcid":false,"given":"Roxana","family":"Coras","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arthur","family":"Kavanaugh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Angela","family":"Kluzniak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dustina","family":"Holt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amy","family":"Weilgosz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Armando","family":"Aaron","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Oswald","family":"Quehenberger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher","family":"Ritchlin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Monica","family":"Guma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,7,24]]},"reference":[{"issue":"10","key":"2575_CR1","doi-asserted-by":"publisher","first-page":"957","DOI":"10.1056\/NEJMra1505557","volume":"376","author":"CT Ritchlin","year":"2017","unstructured":"Ritchlin CT, Colbert RA, Gladman DD. Psoriatic Arthritis. N Engl J Med. 2017;376(10):957\u201370. https:\/\/doi.org\/10.1056\/NEJMra1505557.","journal-title":"N Engl J Med"},{"issue":"10136","key":"2575_CR2","doi-asserted-by":"publisher","first-page":"2273","DOI":"10.1016\/S0140-6736(18)30830-4","volume":"391","author":"DJ Veale","year":"2018","unstructured":"Veale DJ, Fearon U. The pathogenesis of psoriatic arthritis. Lancet. 2018;391(10136):2273\u201384. https:\/\/doi.org\/10.1016\/S0140-6736(18)30830-4.","journal-title":"Lancet."},{"issue":"10","key":"2575_CR3","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1007\/s11926-015-0540-1","volume":"17","author":"A Ogdie","year":"2015","unstructured":"Ogdie A, Gelfand JM. Clinical Risk Factors for the Development of Psoriatic Arthritis Among Patients with Psoriasis: A Review of Available Evidence. Curr Rheumatol Rep. 2015;17(10):64. https:\/\/doi.org\/10.1007\/s11926-015-0540-1.","journal-title":"Curr Rheumatol Rep"},{"issue":"5","key":"2575_CR4","doi-asserted-by":"publisher","first-page":"513","DOI":"10.3945\/an.114.007732","volume":"6","author":"M Gabbs","year":"2015","unstructured":"Gabbs M, Leng S, Devassy JG, Monirujjaman M, Aukema HM. Advances in Our Understanding of Oxylipins Derived from Dietary PUFAs. Adv Nutr. 2015;6(5):513\u201340. https:\/\/doi.org\/10.3945\/an.114.007732.","journal-title":"Adv Nutr"},{"issue":"4","key":"2575_CR5","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1007\/s11306-019-1527-0","volume":"15","author":"R Coras","year":"2019","unstructured":"Coras R, Kavanaugh A, Boyd T, Huynh Q, Pedersen B, Armando AM, et al. Pro- and anti-inflammatory eicosanoids in psoriatic arthritis. Metabolomics. 2019;15(4):65. https:\/\/doi.org\/10.1007\/s11306-019-1527-0.","journal-title":"Metabolomics."},{"issue":"8","key":"2575_CR6","doi-asserted-by":"publisher","first-page":"2665","DOI":"10.1002\/art.21972","volume":"54","author":"W Taylor","year":"2006","unstructured":"Taylor W, Gladman D, Helliwell P, Marchesoni A, Mease P, Mielants H, et al. Classification criteria for psoriatic arthritis: development of new criteria from a large international study. Arthritis Rheum. 2006;54(8):2665\u201373. https:\/\/doi.org\/10.1002\/art.21972.","journal-title":"Arthritis Rheum"},{"issue":"11","key":"2575_CR7","doi-asserted-by":"publisher","first-page":"e142","DOI":"10.1136\/annrheumdis-2019-215960","volume":"79","author":"RSG Goncalves","year":"2019","unstructured":"Goncalves RSG, de Almeida Martins LM, de Ataide MH, Dantas AT, Duarte A. DAPSA versus cDAPSA: Do we need to use CRP? Ann Rheum Dis. 2019;79(11):e142.","journal-title":"Ann Rheum Dis"},{"key":"2575_CR8","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1016\/j.chroma.2014.07.006","volume":"1359","author":"Y Wang","year":"2014","unstructured":"Wang Y, Armando AM, Quehenberger O, Yan C, Dennis EA. Comprehensive ultra-performance liquid chromatographic separation and mass spectrometric analysis of eicosanoid metabolites in human samples. J Chromatogr A. 2014;1359:60\u20139. https:\/\/doi.org\/10.1016\/j.chroma.2014.07.006.","journal-title":"J Chromatogr A"},{"issue":"11","key":"2575_CR9","doi-asserted-by":"publisher","first-page":"3299","DOI":"10.1194\/jlr.M009449","volume":"51","author":"O Quehenberger","year":"2010","unstructured":"Quehenberger O, Armando AM, Brown AH, Milne SB, Myers DS, Merrill AH, et al. Lipidomics reveals a remarkable diversity of lipids in human plasma. J Lipid Res. 2010;51(11):3299\u2013305. https:\/\/doi.org\/10.1194\/jlr.M009449.","journal-title":"J Lipid Res"},{"issue":"12","key":"2575_CR10","doi-asserted-by":"publisher","first-page":"5130","DOI":"10.1073\/pnas.72.12.5130","volume":"72","author":"S Hammarstrom","year":"1975","unstructured":"Hammarstrom S, Hamberg M, Samuelsson B, Duell EA, Stawiski M, Voorhees JJ. Increased concentrations of nonesterified arachidonic acid, 12\u2009L-hydroxy-5,8,10,14-eicosatetraenoic acid, prostaglandin E2, and prostaglandin F2alpha in epidermis of psoriasis. Proc Natl Acad Sci U S A. 1975;72(12):5130\u20134. https:\/\/doi.org\/10.1073\/pnas.72.12.5130.","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"1","key":"2575_CR11","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1016\/0090-6980(84)90113-8","volume":"28","author":"RM Barr","year":"1984","unstructured":"Barr RM, Wong E, Mallet AI, Olins LA, Greaves MW. The analysis of arachidonic acid metabolites in normal, uninvolved and lesional psoriatic skin. Prostaglandins. 1984;28(1):57\u201365. https:\/\/doi.org\/10.1016\/0090-6980(84)90113-8.","journal-title":"Prostaglandins."},{"issue":"1","key":"2575_CR12","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1002\/cia2.12039","volume":"2","author":"T Takeichi","year":"2019","unstructured":"Takeichi T, Kinoshita F, Tanaka H, Fujita S, Kobayashi Y, Nakatochi M, et al. The lipoxygenase-hepoxilin pathway is activated in cutaneous plaque lesions of psoriasis. J Cutan Immunol All. 2019;2(1):15\u201324. https:\/\/doi.org\/10.1002\/cia2.12039.","journal-title":"J Cutan Immunol All"},{"issue":"4","key":"2575_CR13","doi-asserted-by":"publisher","first-page":"1047","DOI":"10.1016\/j.jacl.2018.03.091","volume":"12","author":"AV Sorokin","year":"2018","unstructured":"Sorokin AV, Norris PC, English JT, Dey AK, Chaturvedi A, Baumer Y, et al. Identification of proresolving and inflammatory lipid mediators in human psoriasis. J Clin Lipidol. 2018;12(4):1047\u201360. https:\/\/doi.org\/10.1016\/j.jacl.2018.03.091.","journal-title":"J Clin Lipidol"},{"issue":"4","key":"2575_CR14","doi-asserted-by":"publisher","first-page":"499","DOI":"10.1136\/annrheumdis-2019-216374","volume":"79","author":"M Souto-Carneiro","year":"2020","unstructured":"Souto-Carneiro M, Toth L, Behnisch R, Urbach K, Klika KD, Carvalho RA, et al. Differences in the serum metabolome and lipidome identify potential biomarkers for seronegative rheumatoid arthritis versus psoriatic arthritis. Ann Rheum Dis. 2020;79(4):499\u2013506. https:\/\/doi.org\/10.1136\/annrheumdis-2019-216374.","journal-title":"Ann Rheum Dis"},{"issue":"2","key":"2575_CR15","doi-asserted-by":"publisher","first-page":"631","DOI":"10.1016\/j.jaci.2018.05.036","volume":"143","author":"J Lee","year":"2019","unstructured":"Lee J, Aoki T, Thumkeo D, Siriwach R, Yao C, Narumiya S. T cell-intrinsic prostaglandin E2-EP2\/EP4 signaling is critical in pathogenic TH17 cell-driven inflammation. J Allergy Clin Immunol. 2019;143(2):631\u201343. https:\/\/doi.org\/10.1016\/j.jaci.2018.05.036.","journal-title":"J Allergy Clin Immunol"},{"issue":"3","key":"2575_CR16","doi-asserted-by":"publisher","first-page":"535","DOI":"10.1084\/jem.20082293","volume":"206","author":"K Boniface","year":"2009","unstructured":"Boniface K, Bak-Jensen KS, Li Y, Blumenschein WM, McGeachy MJ, McClanahan TK, et al. Prostaglandin E2 regulates Th17 cell differentiation and function through cyclic AMP and EP2\/EP4 receptor signaling. J Exp Med. 2009;206(3):535\u201348. https:\/\/doi.org\/10.1084\/jem.20082293.","journal-title":"J Exp Med"},{"issue":"7","key":"2575_CR17","doi-asserted-by":"publisher","first-page":"612","DOI":"10.1038\/89759","volume":"2","author":"BD Levy","year":"2001","unstructured":"Levy BD, Clish CB, Schmidt B, Gronert K, Serhan CN. Lipid mediator class switching during acute inflammation: signals in resolution. Nat Immunol. 2001;2(7):612\u20139. https:\/\/doi.org\/10.1038\/89759.","journal-title":"Nat Immunol"},{"issue":"7","key":"2575_CR18","doi-asserted-by":"publisher","first-page":"1518","DOI":"10.1016\/j.jid.2018.02.003","volume":"138","author":"AV Sorokin","year":"2018","unstructured":"Sorokin AV, Domenichiello AF, Dey AK, Yuan ZX, Goyal A, Rose SM, et al. Bioactive Lipid Mediator Profiles in Human Psoriasis Skin and Blood. J Invest Dermatol. 2018;138(7):1518\u201328. https:\/\/doi.org\/10.1016\/j.jid.2018.02.003.","journal-title":"J Invest Dermatol"},{"issue":"2","key":"2575_CR19","doi-asserted-by":"publisher","first-page":"680","DOI":"10.1016\/j.jaci.2018.01.054","volume":"142","author":"Y Ueharaguchi","year":"2018","unstructured":"Ueharaguchi Y, Honda T, Kusuba N, Hanakawa S, Adachi A, Sawada Y, et al. Thromboxane A2 facilitates IL-17A production from Vgamma4(+) gammadelta T cells and promotes psoriatic dermatitis in mice. J Allergy Clin Immunol. 2018;142(2):680\u20133 e2. https:\/\/doi.org\/10.1016\/j.jaci.2018.01.054.","journal-title":"J Allergy Clin Immunol"},{"issue":"4","key":"2575_CR20","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1038\/nrrheum.2014.1","volume":"10","author":"M Korotkova","year":"2014","unstructured":"Korotkova M, Jakobsson PJ. Persisting eicosanoid pathways in rheumatic diseases. Nat Rev Rheumatol. 2014;10(4):229\u201341. https:\/\/doi.org\/10.1038\/nrrheum.2014.1.","journal-title":"Nat Rev Rheumatol"},{"issue":"4","key":"2575_CR21","doi-asserted-by":"publisher","first-page":"406","DOI":"10.1053\/joca.1999.0226","volume":"7","author":"LJ Crofford","year":"1999","unstructured":"Crofford LJ. COX-2 in synovial tissues. Osteoarthr Cartil. 1999;7(4):406\u20138. https:\/\/doi.org\/10.1053\/joca.1999.0226.","journal-title":"Osteoarthr Cartil"},{"key":"2575_CR22","doi-asserted-by":"publisher","unstructured":"Korotkova M, Westman M, Gheorghe KR, af Klint E, Trollmo C, Ulfgren AK, et al. Effects of antirheumatic treatments on the prostaglandin E2 biosynthetic pathway. Arthritis Rheum 2005;52(11):3439-47. https:\/\/doi.org\/10.1002\/art.21390.","DOI":"10.1002\/art.21390"},{"issue":"9","key":"2575_CR23","doi-asserted-by":"publisher","first-page":"e107890","DOI":"10.1371\/journal.pone.0107890","volume":"9","author":"HC Lin","year":"2014","unstructured":"Lin HC, Lin TH, Wu MY, Chiu YC, Tang CH, Hour MJ, et al. 5-Lipoxygenase inhibitors attenuate TNF-alpha-induced inflammation in human synovial fibroblasts. PLoS One. 2014;9(9):e107890. https:\/\/doi.org\/10.1371\/journal.pone.0107890.","journal-title":"PLoS One"},{"issue":"5","key":"2575_CR24","doi-asserted-by":"publisher","first-page":"651","DOI":"10.1172\/JCI0215528","volume":"110","author":"JM McCoy","year":"2002","unstructured":"McCoy JM, Wicks JR, Audoly LP. The role of prostaglandin E2 receptors in the pathogenesis of rheumatoid arthritis. J Clin Invest. 2002;110(5):651\u20138. https:\/\/doi.org\/10.1172\/JCI0215528.","journal-title":"J Clin Invest"},{"issue":"1","key":"2575_CR25","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1186\/s13075-019-1948-1","volume":"21","author":"C Klasen","year":"2019","unstructured":"Klasen C, Meyer A, Wittekind PS, Waque I, Nabhani S, Kofler DM. Prostaglandin receptor EP4 expression by Th17 cells is associated with high disease activity in ankylosing spondylitis. Arthritis Res Ther. 2019;21(1):159. https:\/\/doi.org\/10.1186\/s13075-019-1948-1.","journal-title":"Arthritis Res Ther"},{"issue":"3","key":"2575_CR26","doi-asserted-by":"publisher","first-page":"1364","DOI":"10.4049\/jimmunol.1300274","volume":"191","author":"SM Paulissen","year":"2013","unstructured":"Paulissen SM, van Hamburg JP, Davelaar N, Asmawidjaja PS, Hazes JM, Lubberts E. Synovial fibroblasts directly induce Th17 pathogenicity via the cyclooxygenase\/prostaglandin E2 pathway, independent of IL-23. J Immunol. 2013;191(3):1364\u201372. https:\/\/doi.org\/10.4049\/jimmunol.1300274.","journal-title":"J Immunol"},{"issue":"8","key":"2575_CR27","doi-asserted-by":"publisher","first-page":"2608","DOI":"10.1002\/art.22794","volume":"56","author":"AF Sheibanie","year":"2007","unstructured":"Sheibanie AF, Khayrullina T, Safadi FF, Ganea D. Prostaglandin E2 exacerbates collagen-induced arthritis in mice through the inflammatory interleukin-23\/interleukin-17 axis. Arthritis Rheum. 2007;56(8):2608\u201319. https:\/\/doi.org\/10.1002\/art.22794.","journal-title":"Arthritis Rheum"},{"issue":"Supplement_1","key":"2575_CR28","doi-asserted-by":"publisher","first-page":"i10-i4","DOI":"10.1093\/rheumatology\/keaa039","volume":"59","author":"EG Araujo","year":"2020","unstructured":"Araujo EG, Schett G. Enthesitis in psoriatic arthritis (Part 1): pathophysiology. Rheumatology. 2020;59(Supplement_1):i10-i4.","journal-title":"Rheumatology"},{"issue":"1","key":"2575_CR29","doi-asserted-by":"publisher","first-page":"24","DOI":"10.5152\/eurjrheum.2017.16049","volume":"4","author":"A Moshrif","year":"2017","unstructured":"Moshrif A, Mosallam A, Mohamed EE, Gouda W, Doma M. Subclinical enthesopathy in patients with psoriasis and its association with other disease parameters: a power Doppler ultrasonographic study. Eur J Rheumatol. 2017;4(1):24\u20138. https:\/\/doi.org\/10.5152\/eurjrheum.2017.16049.","journal-title":"Eur J Rheumatol"},{"issue":"17","key":"2575_CR30","doi-asserted-by":"publisher","first-page":"9518","DOI":"10.1111\/jcmm.15669","volume":"24","author":"D Han","year":"2020","unstructured":"Han D, Fang Y, Tan X, Jiang H, Gong X, Wang X, et al. The emerging role of fibroblast-like synoviocytes-mediated synovitis in osteoarthritis: An update. J Cell Mol Med. 2020;24(17):9518\u201332. https:\/\/doi.org\/10.1111\/jcmm.15669.","journal-title":"J Cell Mol Med"},{"issue":"10","key":"2575_CR31","doi-asserted-by":"publisher","first-page":"1838","DOI":"10.1093\/rheumatology\/ker078","volume":"50","author":"E Naredo","year":"2011","unstructured":"Naredo E, Moller I, de Miguel E, Batlle-Gualda E, Acebes C, Brito E, et al. High prevalence of ultrasonographic synovitis and enthesopathy in patients with psoriasis without psoriatic arthritis: a prospective case-control study. Rheumatology (Oxford). 2011;50(10):1838\u201348. https:\/\/doi.org\/10.1093\/rheumatology\/ker078.","journal-title":"Rheumatology (Oxford)"},{"issue":"4","key":"2575_CR32","first-page":"593","volume":"37","author":"F Zuliani","year":"2019","unstructured":"Zuliani F, Zabotti A, Errichetti E, Tinazzi I, Zanetti A, Carrara G, et al. Ultrasonographic detection of subclinical enthesitis and synovitis: a possible stratification of psoriatic patients without clinical musculoskeletal involvement. Clin Exp Rheumatol. 2019;37(4):593\u20139.","journal-title":"Clin Exp Rheumatol"},{"issue":"4","key":"2575_CR33","first-page":"240","volume":"7","author":"AA Alsousi","year":"2017","unstructured":"Alsousi AA, Siddiqui S, Igwe O. Cytokine-mediated Differential Regulation of Cyclooxygenase-2, High Mobility Group Box 1 Protein and Matrix Metalloproteinase-9 Expression in Fibroblast-like Synovial Cells. J Clin Exp Pharmacol. 2017;7(4):240.","journal-title":"J Clin Exp Pharmacol"},{"issue":"6","key":"2575_CR34","doi-asserted-by":"publisher","first-page":"501","DOI":"10.1136\/ard.62.6.501","volume":"62","author":"J Martel-Pelletier","year":"2003","unstructured":"Martel-Pelletier J, Lajeunesse D, Reboul P, Pelletier JP. Therapeutic role of dual inhibitors of 5-LOX and COX, selective and non-selective non-steroidal anti-inflammatory drugs. Ann Rheum Dis. 2003;62(6):501\u20139. https:\/\/doi.org\/10.1136\/ard.62.6.501.","journal-title":"Ann Rheum Dis"},{"issue":"5","key":"2575_CR35","doi-asserted-by":"publisher","first-page":"3383","DOI":"10.4049\/jimmunol.0900327","volume":"183","author":"G Kr\u00f6nke","year":"2009","unstructured":"Kr\u00f6nke G, Katzenbeisser J, Uderhardt S, Zaiss MM, Scholtysek C, Schabbauer G, et al. 12\/15-lipoxygenase counteracts inflammation and tissue damage in arthritis. J Immunol. 2009;183(5):3383\u20139. https:\/\/doi.org\/10.4049\/jimmunol.0900327.","journal-title":"J Immunol"},{"issue":"3","key":"2575_CR36","doi-asserted-by":"publisher","first-page":"R83","DOI":"10.1186\/ar2717","volume":"11","author":"KR Gheorghe","year":"2009","unstructured":"Gheorghe KR, Korotkova M, Catrina AI, Backman L, af Klint E, Claesson HE, et al. Expression of 5-lipoxygenase and 15-lipoxygenase in rheumatoid arthritis synovium and effects of intraarticular glucocorticoids. Arthritis Res Ther. 2009;11(3):R83.","journal-title":"Arthritis Res Ther"},{"issue":"1","key":"2575_CR37","doi-asserted-by":"publisher","first-page":"346","DOI":"10.1007\/s10528-020-10016-9","volume":"59","author":"J Li","year":"2021","unstructured":"Li J, Sun Q, Zheng C, Bai C, Liu C, Zhao X, et al. Lipoxin A4-Mediated p38 MAPK Signaling Pathway Protects Mice Against Collagen-Induced Arthritis. Biochem Genet. 2021;59(1):346\u201365. https:\/\/doi.org\/10.1007\/s10528-020-10016-9.","journal-title":"Biochem Genet"},{"key":"2575_CR38","doi-asserted-by":"crossref","unstructured":"Wojcik P, Biernacki M, Wronski A, Luczaj W, Waeg G, Zarkovic N, et al. Altered Lipid Metabolism in Blood Mononuclear Cells of Psoriatic Patients Indicates Differential Changes in Psoriasis Vulgaris and Psoriatic Arthritis. Int J Mol Sci. 2019;20(17).","DOI":"10.3390\/ijms20174249"}],"container-title":["Arthritis Research &amp; Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13075-021-02575-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13075-021-02575-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13075-021-02575-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,7,24]],"date-time":"2021-07-24T19:04:28Z","timestamp":1627153468000},"score":1,"resource":{"primary":{"URL":"https:\/\/arthritis-research.biomedcentral.com\/articles\/10.1186\/s13075-021-02575-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,7,24]]},"references-count":38,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2021,12]]}},"alternative-id":["2575"],"URL":"https:\/\/doi.org\/10.1186\/s13075-021-02575-y","relation":{},"ISSN":["1478-6362"],"issn-type":[{"value":"1478-6362","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,7,24]]},"assertion":[{"value":"2 March 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 July 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 July 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was approved by the Institutional Board Review of the University of Rochester, New York. Fully informed written consent was obtained from each patient.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"200"}}